menu
    • menu
    [{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tetra Pharm Technologies","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra Pharm Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tetra Pharm Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tetra Pharm Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"TPT0701","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Pharm Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Glysious","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Pharm Technologies \/ Tetra Pharm Technologies"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Kvantify","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Kvantify","highestDevelopmentStatusID":"2","companyTruncated":"Tetra Pharm Technologies \/ Kvantify"}]

    Find Clinical Drug Pipeline Developments & Deals by Tetra Pharm Technologies

    Menu

    Tetra Pharm Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Kvantify

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tetra Pharm and Kvantify Announce Partnership for Endocannabinoid Drug Discovery

                            Details : The partnership aims to accelerate the identification and development of novel small molecule drug candidates targeting the endocannabinoid system (ECS).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Kvantify

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPT0201

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Glysious

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tetra Pharm and Glysious Partner to Develop Transdermal Endocannabinoid System Drugs

                            Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.

                            Brand Name : TPT0201

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : TPT0201

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Glysious

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPT0701

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tetra Pharm Advances CB1 Antagonist TPT0701 Into Preclinical Testing

                            Details : TPT0701 is a CB1 receptor antagonist being evaluated in preclinical studies for obesity treatment, offering a novel approach to appetite suppression.

                            Brand Name : TPT0701

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            February 08, 2024

                            Lead Product(s) : TPT0701

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabinoid

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tetra Pharm Technologies Launches First Product in Germany

                            Details : Company is launching its first product, XATEPA®, on the German market. XATEPA® is based on cannabinoids, being indiacated for the treament of neuropathic pain, sclerosis and mental health disorders.

                            Brand Name : Xatepa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 03, 2023

                            Lead Product(s) : Cannabinoid

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tetra Pharm Technologies

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : $9.7 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tetra Pharm Technologies Secures €9 Million In Series A Round to Expand R&D Operations

                            Details : Tetra Pharm Technologies will use the net proceeds to increase its capacity in Research and Development and expand its commercial operations internationally.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : $9.7 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth